Drug for erectile disorder show promise in the treatment of obesity

"There is a growing need for novel treatments against obesity," said Alexander Pfeifer, M.D., Ph.D., a researcher involved in the work from the Institute of Pharmacology and Toxicology at the University of Bonn, Biomedical Center in Bonn, Germany. "Finding new positive effects of existing drugs, such as sildenafil, in adipose tissue might help to bridge the period until novel drugs against obesity have been developed."

To make this discovery, Pfeifer and colleagues used mice to show that cyclic GMP reduced the secretion of pro-inflammatory hormones, which, in turn, shifted the "color code" of fat from white to brown. Mice treated with sildenafil showed browning of the white fat after just a few days of treatment, which is believed to be the result of high cyclic GMP levels. Then the researchers used isolated fat cells and treated the cells directly with cyclic GMP and identified a "browning" effect as well.

"Clearly, size matters when it comes to our weight," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "Numerous studies show that obesity is a risk factor for virtually every human disease, and that obesity is epidemic. The finding that Viagra® and similar drugs can change our body fat composition has major implications. These drugs have well defined risk/benefit profiles and are approved for the treatment of erectile disorders. Further research will determine whether they are useful in the treatment of human girth disorders."